{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T10:29:34Z","timestamp":1773138574389,"version":"3.50.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["OneCDP 214515"],"award-info":[{"award-number":["OneCDP 214515"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1136\/ijgc-2023-004487","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T12:56:11Z","timestamp":1693313771000},"page":"1602-1611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1073-8688","authenticated-orcid":false,"given":"Dana M","family":"Chase","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anadi","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Alexander","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Kalilani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-004487_bb0010","first-page":"209","article-title":"Global cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2023-004487_bb0015","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-019-0579-0","article-title":"Maintenance therapy for recurrent epithelial ovarian cancer: Current therapies and future perspectives - a review","volume":"12","author":"Gupta","year":"2019","journal-title":"J Ovarian Res"},{"key":"10.1136\/ijgc-2023-004487_bb0020","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13048-022-01020-1","article-title":"Maintenance therapy for newly diagnosed epithelial ovarian cancer\u2013 a review","volume":"15","author":"Nag","year":"2022","journal-title":"J Ovarian Res"},{"key":"10.1136\/ijgc-2023-004487_bb0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/annonc\/mdi104","article-title":"Prognostic factors in ovarian cancer: how close are we to a complete picture","volume":"16","author":"Agarwal","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0030","unstructured":"FDA . Clinical-trial-endpoints-approval-cancer-drugs-Biologics-final-guidance."},{"issue":"Suppl 2","key":"10.1136\/ijgc-2023-004487_bb0035","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.3747\/co.v18i0.939","article-title":"Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective","volume":"18 Suppl 2","author":"Oza","year":"2011","journal-title":"Curr Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0040","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918788500","article-title":"Progression-free survival as a Surrogate Endpoint for overall survival in modern ovarian cancer trials: a meta-analysis","volume":"10","author":"Sjoquist","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0045","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1136\/ijgc-2023-004487_bb0050","author":"Peterson","year":"2021","journal-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of Nonrandomised studies in meta-analyses"},{"key":"10.1136\/ijgc-2023-004487_bb0055","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/00949650108812071","article-title":"Estimating the variance of the sample median","volume":"68","author":"Price","year":"2001","journal-title":"Journal of Statistical Computation and Simulation"},{"key":"10.1136\/ijgc-2023-004487_bb0060","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ygyno.2014.10.003","article-title":"Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer","volume":"135","author":"Ataseven","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0065","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2015.12.007","article-title":"Prognostic impact of Debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV","volume":"140","author":"Ataseven","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0070","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1245\/s10434-018-6683-3","article-title":"Skeletal muscle Attenuation (Sarcopenia) predicts reduced overall survival in patients with advanced epithelial ovarian cancer undergoing primary Debulking surgery","volume":"25","author":"Ataseven","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0075","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/bjc.2011.455","article-title":"Role of histological type on surgical outcome and survival following radical primary tumour Debulking of epithelial ovarian, Fallopian tube and peritoneal cancers","volume":"105","author":"Braicu","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2023-004487_bb0080","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ygyno.2011.04.047","article-title":"Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center","volume":"122","author":"Bristow","year":"2011","journal-title":"Gynecologic Oncology"},{"key":"10.1136\/ijgc-2023-004487_bb0085","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1245\/s10434-012-2446-8","article-title":"Impact of complete Cytoreduction leaving no gross residual disease associated with radical Cytoreductive surgical procedures on survival in advanced ovarian cancer","volume":"19","author":"Chang","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0090","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.2147\/OTT.S67812","article-title":"A survival analysis comparing women with ovarian low-grade Serous carcinoma to those with high-grade histology","volume":"7","author":"Chen","year":"2014","journal-title":"Onco Targets Ther"},{"key":"10.1136\/ijgc-2023-004487_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00355","article-title":"Survival analysis of lymph node resection in ovarian cancer: A population-based study","volume":"10","author":"Cheng","year":"2020","journal-title":"Front Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0100","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ygyno.2018.12.011","article-title":"Surgical complexity score and role of Laparoscopy in women with advanced ovarian cancer treated with Neoadjuvant chemotherapy","volume":"152","author":"Davidson","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030768","article-title":"30 years of experience in the management of stage III and IV epithelial ovarian cancer: impact of surgical strategies on survival","volume":"12","author":"Delga","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2023-004487_bb0110","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-017-0331-6","article-title":"Age is associated with prognosis in Serous ovarian carcinoma","volume":"10","author":"Deng","year":"2017","journal-title":"J Ovarian Res"},{"key":"10.1136\/ijgc-2023-004487_bb0115","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1245\/s10434-016-5686-1","article-title":"Cytoreduction (Peritonectomy procedures) combined with Hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: retrospective Italian multicenter observational study of 511 cases","volume":"24","author":"Di Giorgio","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0120","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ygyno.2013.11.035","article-title":"Does Neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study","volume":"132","author":"Fag\u00f6-Olsen","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0125","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ygyno.2016.04.016","article-title":"Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade Serous ovarian cancer","volume":"141","author":"Feng","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0130","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/IGC.0000000000000843","volume":"27","author":"Gadducci","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004487_bb0135","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-019-0562-9","article-title":"Evaluating the benefits of Neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study","volume":"12","author":"Gao","year":"2019","journal-title":"J Ovarian Res"},{"key":"10.1136\/ijgc-2023-004487_bb0140","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s10147-011-0223-5","article-title":"Comparison between Serous and non-Serous ovarian cancer as a Prognostic factor in advanced epithelial ovarian carcinoma after primary Debulking surgery","volume":"16","author":"Hosono","year":"2011","journal-title":"Int J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0145","doi-asserted-by":"crossref","DOI":"10.1186\/1757-2215-5-20","article-title":"High preoperative blood levels of He4 predicts poor prognosis in patients with ovarian cancer","volume":"5","author":"Kalapotharakos","year":"2012","journal-title":"J Ovarian Res"},{"key":"10.1136\/ijgc-2023-004487_bb0150","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ygyno.2016.05.027","article-title":"Muscle composition measured by CT scan is a measurable Predictor of overall survival in advanced ovarian cancer","volume":"142","author":"Kumar","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ygyno.2011.06.031","article-title":"Morbidity, mortality and overall survival in elderly women undergoing primary surgical Debulking for ovarian cancer: a delicate balance requiring Individualization","volume":"123","author":"Langstraat","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0160","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/IGC.0b013e31826a3559","article-title":"Maximal Cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, Fallopian, and peritoneal cancer in day-to-day practice: a retrospective French Multicentric study","volume":"22","author":"Luyckx","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004487_bb0165","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ygyno.2018.06.015","article-title":"\u201cMoving beyond \"complete surgical resection\" and \"optimal\": is low-volume residual disease another option for primary Debulking surgery\u201d","volume":"150","author":"Manning-Geist","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0170","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1097\/IGC.0000000000000241","article-title":"Primary surgery or interval Debulking for advanced epithelial ovarian cancer: does it matter","volume":"24","author":"Markauskas","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004487_bb0175","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ygyno.2017.08.003","article-title":"Associations between residual disease and survival in epithelial ovarian cancer by histologic type","volume":"147","author":"Melamed","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0180","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/bjc.2015.97","article-title":"Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients","volume":"112","author":"Mizuno","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2023-004487_bb0185","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejso.2015.11.006","article-title":"Peritonectomy procedures and HIPEC in the treatment of peritoneal Carcinomatosis from ovarian cancer: long-term outcomes and perspectives from a high-volume center","volume":"42","author":"Mu\u00f1oz-Casares","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0190","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/bjc.2017.83","article-title":"Methylation of Mylk3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a Multicentre study","volume":"116","author":"Phelps","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2023-004487_bb0195","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.ejso.2018.01.097","article-title":"Complete Cytoreduction after five or more cycles of Neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer","volume":"44","author":"Phillips","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0200","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-017-0363-y","article-title":"Endometriosis is the independent Prognostic factor for survival in Chinese patients with epithelial ovarian carcinoma","volume":"10","author":"Ren","year":"2017","journal-title":"J Ovarian Res"},{"key":"10.1136\/ijgc-2023-004487_bb0205","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1525-1","article-title":"Radical surgery versus standard surgery for primary Cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study","volume":"15","author":"Ren","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1136\/ijgc-2023-004487_bb0210","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/IGC.0000000000001173","article-title":"Specific regions, rather than the entire peritoneal Carcinosis index, are predictive of complete resection and survival in advanced epithelial ovarian cancer","volume":"28","author":"Rosendahl","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004487_bb0215","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ejso.2016.12.016","article-title":"The influence of Sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary Debulking surgery","volume":"43","author":"Rutten","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0220","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/464123","article-title":"Prognostic value of residual disease after interval Debulking surgery for FIGO stage IIIC and IV epithelial ovarian cancer","volume":"2015","author":"Rutten","year":"2015","journal-title":"Obstet Gynecol Int"},{"key":"10.1136\/ijgc-2023-004487_bb0225","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ygyno.2020.04.048","article-title":"Prolonged interruption of chemotherapy in patients undergoing delayed Debulking surgery for advanced high grade Serous ovarian cancer is associated with a worse prognosis","volume":"158","author":"Searle","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0230","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/aogs.13453","article-title":"Impact of residual disease on overall survival in women with Federation of Gynecology and obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery","volume":"98","author":"S\u00f8rensen","year":"2019","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1136\/ijgc-2023-004487_bb0235","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ygyno.2018.07.004","article-title":"Interval between Debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer","volume":"150","author":"Timmermans","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0240","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ejca.2012.01.031","article-title":"Neoadjuvant chemotherapy, interval Debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV","volume":"48","author":"Trop\u00e9","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2023-004487_bb0245","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/AOG.0b013e3182a054ee","article-title":"Efficacy of a regional network for ovarian cancer care","volume":"122","author":"van Altena","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2023-004487_bb0250","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.ejso.2020.04.029","article-title":"Prognostic factors of overall survival for patients with FIGO stage Iiic or Iva ovarian cancer treated with Neo-adjuvant chemotherapy followed by interval Debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group","volume":"46","author":"Vincent","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0255","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijsu.2018.02.006","article-title":"The effect of Lymphadenectomy in advanced ovarian cancer according to residual tumor status: A population-based study","volume":"52","author":"Zhou","year":"2018","journal-title":"Int J Surg"},{"key":"10.1136\/ijgc-2023-004487_bb0260","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/AOG.0000000000002796","article-title":"Laparoscopic surgical algorithm to triage the timing of tumor Reductive surgery in advanced ovarian cancer","volume":"132","author":"Fleming","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2023-004487_bb0265","doi-asserted-by":"crossref","DOI":"10.1186\/1757-2215-6-42","article-title":"Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium","volume":"6","author":"Trillsch","year":"2013","journal-title":"J Ovarian Res"},{"key":"10.1136\/ijgc-2023-004487_bb0270","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/AOG.0b013e31829ce7ec","article-title":"Survival in women with grade 1 Serous ovarian carcinoma","volume":"122","author":"Nickles Fader","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2023-004487_bb0275","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2018.08.036","article-title":"Exploratory outcome analyses according to stage and\/or residual disease in the Icon7 trial of carboplatin and paclitaxel with or without Bevacizumab for newly diagnosed ovarian cancer","volume":"152","author":"Gonz\u00e1lez Mart\u00edn","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0280","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/annonc\/mdv500","article-title":"Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG oncology\/gynecologic oncology group study","volume":"27","author":"Tewari","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0285","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2013.04.001","article-title":"Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a gynecologic oncology group study","volume":"130","author":"Landrum","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0290","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2012.07.023","article-title":"Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials","volume":"49","author":"Mahner","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2023-004487_bb0295","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2013.06.017","article-title":"Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of gynecologic oncology group (GOG) 182","volume":"130","author":"Rodriguez","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0300","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/cncr.30414","article-title":"What is the role of Retroperitoneal exploration in Optimally Debulked stage IIIC epithelial ovarian cancer? an NRG oncology\/gynecologic oncology group ancillary data study","volume":"123","author":"Rungruang","year":"2017","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2023-004487_bb0305","doi-asserted-by":"crossref","first-page":"7","DOI":"10.31083\/j.ejgo.2020.01.4826","article-title":"Prognostic factors for types I and II epithelial ovarian cancer in the elderly","volume":"41","author":"Cheng","year":"2020","journal-title":"EJGO"},{"key":"10.1136\/ijgc-2023-004487_bb0310","unstructured":"NICE . The guidelines manual: Appendix C: methodology checklist: randomised controlled trials, the guidelines manual: Appendix C;"},{"key":"10.1136\/ijgc-2023-004487_bb0315","author":"Wells","year":"2021","journal-title":"Newcastle - Ottawa quality assessment scale case control studies"},{"key":"10.1136\/ijgc-2023-004487_bb0320","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrclinonc.2013.5","article-title":"Latest research and treatment of advanced-stage epithelial ovarian cancer","volume":"10","author":"Coleman","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0325","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/annonc\/mdv562","article-title":"Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents","volume":"27","author":"Saad","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0330","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2017.08.012","article-title":"FDA ovarian cancer clinical trial endpoints workshop: A society of gynecologic oncology white paper","volume":"147","author":"Herzog","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0335","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of Bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004487_bb0340","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004487_bb0345","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004487_bb0350","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of Bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004487_bb0355","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004487_bb0360","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/annonc\/mdy514","article-title":"Exaggeration of PFS by blinded, independent, central review (BICR)","volume":"30","author":"Stone","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0365","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(22)00139-5","article-title":"Clinical research in ovarian cancer: consensus recommendations from the gynecologic cancer Intergroup","volume":"23","author":"Vergote","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0370","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejca.2011.10.028","article-title":"Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?","volume":"48","author":"Amir","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2023-004487_bb0375","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18939","article-title":"Assessment of progression-free survival as a Surrogate end point of overall survival in first-line treatment of ovarian cancer: A systematic review and meta-analysis","volume":"3","author":"Paoletti","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1136\/ijgc-2023-004487_bb0380","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance Olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA Mutation: the Solo1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0385","doi-asserted-by":"crossref","first-page":"S1396","DOI":"10.1016\/j.annonc.2022.08.025","article-title":"Final overall survival (OS) results from the phase IIIPAOLA-1\/ENGOT-Ov25 trial evaluating maintenance Olaparib(Ola) plus Bevacizumab (BEV) in patients (Pts) with Newly diagnosed advanced ovarian cancer (AOC)","volume":"33","author":"Ray-Coquard","year":"2022","journal-title":"Annals of Oncology"},{"key":"10.1136\/ijgc-2023-004487_bb0390","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-85696-3","article-title":"Real-world outcomes versus clinical trial results of Immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands","volume":"11","author":"Cramer-van der Welle","year":"2021","journal-title":"Sci Rep"},{"key":"10.1136\/ijgc-2023-004487_bb0395","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.18.01074","article-title":"Comparison of population-based observational studies with randomized trials in oncology","volume":"37","author":"Soni","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004487_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.08.1203","article-title":"761P impact of residual disease on outcomes in patients with ovarian cancer: A meta-analysis","volume":"32","author":"Chase","year":"2021","journal-title":"Annals of Oncology"},{"key":"10.1136\/ijgc-2023-004487_bb0405","doi-asserted-by":"crossref","first-page":"595789","DOI":"10.3389\/fonc.2020.595789","article-title":"Histological characteristics and early-stage diagnosis are associated with better survival in young patients with epithelial ovarian cancer: A retrospective analysis based on surveillance epidemiology and end results database","volume":"10","author":"Huang","year":"2020","journal-title":"Front Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24017146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24017146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-004487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:40:56Z","timestamp":1753224056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24017146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":80,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1048891X24017146"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-004487","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-004487","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/.","name":"copyright","label":"Copyright"}]}}